Needham analyst Mike Matson reiterated a Buy rating and $112.00 price target on Haemonetics (NYSE: HAE).The analyst commented: "HAE's F2Q25 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE